Ranibizumab and Reduced Fluence PDT for AMD (RAP)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.
| Condition | Intervention | Phase |
|---|---|---|
|
Macular Degeneration |
Drug: ranibizumab Drug: verteporfin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration |
- The primary outcome will be the percentage of patients with less than 15 letters of visual loss at 12 months. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- The number of days to retreatment. The total number of treatments given over one year. The percentage of patients with more than a 15 letter increase in vision at 12 months. The mean change in macular volume as measured by OCT at 3, 6, and 12 months. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2007 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Group I
Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
|
Drug: ranibizumab
0.5 mg. given as an intraocular injection
|
|
Experimental: Group II
Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
|
Drug: ranibizumab
0.5 mg. given as an intraocular injection
Drug: verteporfin
Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
|
Detailed Description:
A randomized, prospective, multicenter trial will compare two groups of patients with subfoveal choroidal neovascularization secondary to AMD. One group will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year. The other group will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year. Re-treatment will be determined by the individual investigator based on visual acuity, retinal thickness as measured by optical coherence tomography (OCT), and fluorescein angiography. Visual acuity and OCT measurements will be performed by masked examiners.
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Willingness to sign informed consent.
- Age greater than 50.
- Evidence of macular degeneration in the form of drusen in either eye.
- Visual acuity of 20/25 to 20/800.
Subfoveal choroidal neovascularization. Both occult and classic subtypes will be allowed. If lesion is purely occult there has to be one of the following:
- Recent loss of vision (5 letters on ETDRS or doubling of visual angle by snellen)
- Documented enlargement of lesion on FA
- Increase of 50 microns or more in the central subfield on OCT
- New blood
- Total active lesion must be less than 12 disc areas in size. -
Exclusion Criteria:
- Myopia, ocular histoplasmosis, or other retinal pathology that could affect vision
- Previous treatment of the enrolled eye for CNV
- Intraocular surgery within 6 weeks of enrollment
- Geographic atrophy, subretinal fibrosis, or pigment epithelial tear involving the fovea of the eligible eye
- Known hypersensitivity to verteporfin
- Medical condition that would preclude regular follow-up for one year.
- Previous vitrectomy
- Media opacities limiting visual acuity, retinal examination, or retinal imaging.
- A lesion where > 50% of the lesion is a pigment epithelial detachment. -
Contacts and Locations| United States, California | |
| California Retina Consultants & Research Foundation | |
| Santa Barbara, California, United States, 93103 | |
| United States, Michigan | |
| Associated Retinal Consultants | |
| Ann Arbor, Michigan, United States, 49301 | |
| United States, Texas | |
| Texas Retina Associates | |
| Arlington, Texas, United States, 76012 | |
| Study Chair: | David Callanan, MD | Texas Retina Associates |
More Information
No publications provided
| Responsible Party: | David Callanan, Texas Retina Associates |
| ClinicalTrials.gov Identifier: | NCT00527475 History of Changes |
| Other Study ID Numbers: | RAP AMD Trial |
| Study First Received: | September 9, 2007 |
| Last Updated: | September 27, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Texas Retina Associates:
|
Anti-VEGF therapy photodynamic therapy neovascularization |
Additional relevant MeSH terms:
|
Macular Degeneration Neovascularization, Pathologic Choroidal Neovascularization Retinal Degeneration Retinal Diseases Eye Diseases Metaplasia Pathologic Processes Choroid Diseases |
Uveal Diseases Verteporfin Photosensitizing Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions Dermatologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013